Status:

COMPLETED

Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension

Lead Sponsor:

AstraZeneca

Conditions:

Acute Coronary Syndromes

Eligibility:

All Genders

Brief Summary

This study is to describe the long-term antithrombotic management patterns in a real-life setting for patients hospitalized with an acute coronary syndrome in China.

Detailed Description

This study is to describe the long-term (3 to 5 years after the acute coronary syndrome index event) antithrombotic management patterns in a real-life setting for patients hospitalized with an acute c...

Eligibility Criteria

Inclusion

  • Written informed consent has been provided.
  • Contact Order Form has been provided
  • Aged 18 years or older.
  • Enrolled in EPICOR Asia study and completed the 2 year follow-up.

Exclusion

  • Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances, alcohol or drug abuse).
  • Already included in the EPICOR Asia-China Extension observational study.
  • Presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy.
  • Current participation in an interventional clinical trial.
  • Patients receiving ticagrelor beyond 12 months and other off label use.

Key Trial Info

Start Date :

December 17 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

April 5 2017

Estimated Enrollment :

2334 Patients enrolled

Trial Details

Trial ID

NCT02305680

Start Date

December 17 2014

End Date

April 5 2017

Last Update

September 17 2018

Active Locations (33)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (33 locations)

1

Research Site

Baoding, China

2

Research Site

Beijing, China

3

Research Site

Changzhi, China

4

Research Site

Chongqing, China